Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): results from a multi-center Phase II trial
UT Southwestern Medical Center
Testosterone fuels the growth of prostate cancer. The target of testosterone is the androgen receptor. Metastatic prostate cancer is treated by reducing levels of testosterone, and despite initial responses to treatment, nearly all patients become resistant to androgen deprivation therapy.
Patients being treated for HPV-related oropharynx cancer might need less radiation therapy typically given post-surgery, according to a new study.
Scientists from the American Cancer Society (ACS) are presenting important research studies at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2024.
In honor of their outstanding contributions to the field of oncology, two researchers from The University of MD Anderson Cancer Center will be honored with Special Awards at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week.
“The COAST study, which we began five years ago, involves patients who get chemotherapy and radiation therapy for lung cancer. And now we know that we can improve the outcome with a drug called durvalumab,” explained Dr. Herbst, who will present the findings at ASCO.
Cedars-Sinai Cancer physician-scientists and thought leaders will discuss scientific advances, new therapies, and the future of cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4 in Chicago.
A new study(Link is external) (Link opens in new window) led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup of cancer cells that were associated with race and ethnicity.